Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Alert advises on need to remain vigilant, especially in patients with increased bleeding risks; and that specific reversal agents are available for dabigatran (Praxbind, [idarucizumab]), apixaban and rivaroxaban (Ondexxya [andexanet alfa]).

Source:

Medicines and Healthcare products Regulatory Agency